Objective. To analyze the composition of known plasmacytosis in systemic lupus erythematosus (SLE) to obtain further insight into the nature of underlying mechanisms.
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Objective. To analyze the composition of known plasmacytosis in systemic lupus erythematosus (SLE) to obtain further insight into the nature of underlying mechanisms.
Methods. Plasmablasts from patients with active SLE, patients with inactive/treated SLE, and healthy controls were characterized by flow cytometry, enzymelinked immunospot assay, and Transwell migration assays and compared to vaccination-induced plasmablasts. Serum cytokine levels were analyzed by Luminex assay, and histologic analysis of kidney biopsy specimens was performed.
Results. Circulating plasmablasts in SLE expressed markers of mucosal immune reactions. IgA, CCR10, and b7 integrin were expressed by 48%, 40%, and 38% of plasmablasts, respectively, with varying coexpression patterns. Consistent with mucosal homing, some SLE plasmablasts migrated toward the mucosal chemokine CCL28 and secreted polymeric IgA. SLE plasmablasts shared phenotypic characteristics with antigen-specific plasmablasts induced by oral, but not parenteral, vaccinations. Autoreactive antibody-secreting cells of the IgG and IgA isotypes were detectable, but only the emergence of phenotypically mucosal plasmablasts was positively associated with serum interleukin-2 and platelet-derived growth factor BB levels.
Conclusion. Our data suggest that distinct plasmablast differentiation pathways jointly contribute to peripheral plasmacytosis in SLE, i.e., a cytokineamplified mucosal "steady-state" plasmablast response, and an autoreactive plasmablast response, representing conventional autoimmunity. Our results indicate an overly activated mucosal immune system in patients with SLE, with both immunologic and clinical implications.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that often affects multiple organs and organ systems. At the level of the immune system, it is not only characterized by a complex dysregulation of cellular and humoral adaptive immune responses, but also of innate immune functions (1) . B cells, and specifically antibody-secreting plasma cells (PCs) and their immediate precursors, plasmablasts, have gained special interest in SLE since they directly cause distinctive immunologic symptoms: hypergammaglobulinemia, immune complex formation, and the production of autoantibodies. SLE patients exhibit defective B cell selection, including abnormal germinal center responses, B lymphopenia, and disturbed composition of the remaining peripheral B cells (2,3) with a marked expansion of antibody-secreting plasmablasts (2, 4) . Plasmablasts are positively associated with lupus disease activity, as well as with the presence of serum autoantibodies and titers (2, 4) , and therapeutic targeting of autoreactive PCs is discussed as a future treatment option for SLE (5) .
In healthy individuals who have not been immunized recently, plasmablasts are continuously detectable in the blood at very low frequencies. Most of these plasmablasts appear to be generated in mucosal immune reactions of the gut and/or airways, as indicated by the expression of the prototypical immunoglobulin of mucosal immune reactions, IgA, and of the mucosal homing receptors CCR10 and a4b7 integrin (6,7), as well as by secretion of polymeric IgA (8) .
IgA expression results from class-switch recombination of activated B cells under the influence of transforming growth factor b (TGFb), occurring predominantly in mucosal tissues (7) , and is therefore considered a marker of mucosal B cell activation. The a4b7 integrin mediates adhesion to mucosal addressin cell adhesion molecule 1 (MAdCAM-1) expressed on high endothelial venules (HEVs) of mucosal tissues of the gastrointestinal (GI) tract. Consistently, a4b7 integrinpositive plasmablasts are capable of initiating homing to the gut, while a4b7 integrin-negative plasmablasts can use a4b1 integrin to adhere to vascular cell adhesion molecule 1-positive HEVs of the trachea and bronchoalveolar tissues (9, 10) . Expression of a4b7 integrin in B cells is triggered by retinoic acid produced by dendritic cells (DCs) residing in gut-or airway-associated lymphoid tissue, but not other DCs (11, 12) , and is therefore used as a reliable identifier of not only mucosal homing, but also mucosal priming, of a4b7 integrin-positive cells. The chemokine receptor CCR10 mediates plasmablast chemotaxis along gradients of CCL28, which is expressed in all mucosal tissues (13) . Skin-expressed CCL27 can also bind to CCR10 (14) . Unlike CCR9, which specifically mediates homing to the small intestine (7), CCR10 does not select for migration to a specific mucosal site and appears to be important for homing to the nonintestinal mucosa (15) .
In mucosal PC deposits, most PCs express CCR10, b7 integrin, and IgA (15, 16) , including 60% coexpressing the J-chain (16) for formation of polymeric IgA that is dedicated to its secretion at mucosal surfaces (17) . The a4b7 integrin, IgA, and CCR10 are expressed by many but not all circulating plasmablasts specific for mucosally administered vaccines or enteric pathogens (18, 19) . Indeed, multiple, partially redundant molecular pathways exist that mediate plasmablast homing into different mucosal locations (7, 20, 21) . In this study, we base our analyses on our own vaccination data, which show exclusive expression of b7 integrin and CCR10 by antigen-specific plasmablasts in blood after mucosal, but not after systemic (i.e., intramuscular or subcutaneous), vaccination.
Generally, the accumulation of plasmablasts in the blood of SLE patients is thought to result from B cell hyperactivity. Consistent with aberrant B cell stimulation by an autoantigen, autoreactive plasmablasts have been found in the blood of SLE patients (22) . Despite the longstanding interest in plasmablasts as biomarkers and potential therapeutic targets, their composition and origin in SLE have not been explicitly addressed. To better understand the differentiation of plasmablasts and the mechanism(s) underlying plasmacytosis in SLE, we conducted a cross-sectional study of patients with active SLE and patients with treated, inactive SLE to investigate quantitative and qualitative characteristics of plasmablasts with a focus on mucosal traits. Isolation of peripheral blood mononuclear cells (PBMCs). PBMCs were isolated as previously described (23), with optional depletion of T cells and monocytes by rosetting (StemCell Technologies).
PATIENTS AND METHODS

Detailed information on
Flow cytometric analysis. Flow cytometry was performed on a FACSCanto II or LSRII flow cytometer (BD Biosciences) using fluorochrome-conjugated monoclonal antibodies. Fluorescence-labeled antigen was used to detect antigen-specific B cells (23, 24) .
In vitro antibody secretion and enzyme-linked immunospot (ELISpot) assay. PBMCs were incubated in media for 2 days, allowing for spontaneous antibody secretion. Detection of polymeric and monomeric IgA in PBMC supernatants was achieved by subjecting supernatants or control samples to fastprotein liquid chromatography, followed by the detection of IgA by enzyme-linked immunosorbent assay (ELISA) in the collected fractions. ELISpot assays were performed as previously described (23) (24) (25) .
Cytokine quantification. Serum cytokines were quantified by ELISA and Luminex assays (Bio-Rad). In vitro chemotaxis was assessed using a Transwell migration assay as previously described (6) .
Histologic analysis. Histologic analysis was performed on kidney biopsy sections by periodic acid-Schiff, IgG, and IgA staining.
Statistical analysis. Cytometric data were analyzed using FlowJo (Tree Star). ELISA data were analyzed using SoftMax Pro software version 5 (Molecular Devices). Data were statistically analyzed and displayed in GraphPad Prism. Statistical significance was calculated using the Mann-Whitney test for comparisons between patients and controls (2-tailed, 95% confidence interval), and Wilcoxon's test for paired comparisons, except where otherwise indicated. Spearman's rank correlation combined with bootstrap resampling (26) was used to correlate cytokine and cytometric data.
RESULTS
IgA1 plasmablasts contribute to the increased levels of circulating plasmablasts in SLE patients. Plasmablasts, naive B cells, and memory B cells were quantified in blood samples from 32 SLE patients and 19 healthy donors ( Figure 1A ). As previously reported (2), B lymphopenia in SLE affected naive B cells and memory B cells, while plasmablast numbers and frequencies were increased in SLE patients versus healthy donors (2. . Consistent with the inclusion of patients with largely inactive, controlled disease, the correlation between disease activity and plasmablast frequency was less striking than in previous reports (4) (r 5 0.27, P 5 0.13) (data not shown).
Similar proportions of plasmablasts from SLE patients and controls expressed cell-surface IgA, at median levels of 58% and 55%, respectively (P 5 0.49). Accordingly, numbers of both IgA1 and IgA-plasmablasts were increased in SLE patients compared to healthy donors (2.5-fold [P 5 0.0003] for IgA1 plasmablasts and 1.5-fold [P 5 0.0017] for IgA-plasmablasts) ( Figures 1A and B) . Since increased frequencies of IgA1 plasmablasts were evident both in patients with high disease activity and in those with low disease activity and both in patients with high and in those with low absolute numbers of plasmablasts or plasmablast frequencies (data not shown), no association between IgA1 plasmablasts and the overall emergence of peripheral plasmablasts and SLE disease activity was established.
In an independent analysis of 4 healthy donor and 6 SLE samples, the predominance of IgA1 plasmablasts was confirmed by the detection of cytoplasmic IgA, IgG, and IgM among PBMCs. While cytoplasmic IgA-positive and cytoplasmic IgG-negative cells were detectable at comparable median frequencies among total plasmablasts in SLE patients and controls (for IgA, 66% in SLE patients and 64% in healthy donors, and for IgG, 29% in SLE patients and 23% in healthy donors), frequencies of cytoplasmic IgM-positive plasmablasts were significantly reduced in SLE patients (4% in SLE patients versus 11% in healthy donors; P , 0.001) ( Figure 1C ). These data confirm the expansion of plasmablasts in the peripheral blood of SLE patients and indicate that the expanded plasmablast 1/intermediate CD38 high PBMCs from 6 SLE patients and 4 controls. Pie charts show the mean percentage of plasmablasts expressing cytoplasmic IgG, cytoplasmic IgA, and cytoplasmic IgM. The total area of the pie reflects the median frequency of plasmablasts among PBMCs, which was 2.25-fold higher in the SLE patients than in the controls. Patients in B and C exhibited similar levels of disease activity (mean 6 SD SLE Disease Activity Index 8.5 6 2.9 and 9.7 6 1.8, respectively). ** 5 P , 0.01; *** 5 P , 0.001 by Mann-Whitney 2-tailed test.
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MEI ET AL population consists predominantly of IgA1 plasmablasts, followed by IgG1 plasmablasts and diminished amounts of IgM1 plasmablasts. Expression of mucosal homing receptors by circulating plasmablasts in SLE. CCR10 and b7 integrin were expressed by SLE plasmablasts at median frequencies of 40% and 38%, respectively (Figure 2A) . The intestinal chemokine receptor CCR9 was not found on plasmablasts in SLE patients or controls (,1.4% of plasmablasts, except for 1 sample from a healthy donor that expressed CCR9 on 7% of plasmablasts). Likewise, SLE plasmablasts lacked expression of cutaneous lymphocyte antigen (CLA) involved in skin homing (,1.4% of plasmablasts). Frequencies of CCR101 plasmablasts did not differ significantly between patients and healthy donors (P . 0.05), while frequencies of b7 integrin-positive plasmablasts were diminished in SLE patients (P 5 0.037) (Supplementary Table  3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40181/ abstract). Thus, CCR101, CCR10-, and b7 integrinnegative plasmablasts clearly contributed to the expansion of plasmablasts in SLE. b7 integrin-positive plasmablasts were expanded to more than 2.2 cells/ml (a threshold set according to the maximum value in healthy donors, not considering the outlier) in a subgroup of 9 SLE patients, 6 of whom had active SLE (Figure 2A and Supplementary Table 3) .
IgA, b7 integrin, and CCR10 expression were simultaneously analyzed to study their coexpression pattern on plasmablasts. CCR10 and b7 integrin were expressed by IgA1 plasmablasts but also by IgAplasmablasts, i.e., IgM1 or IgG1 plasmablasts, indicating that a significant proportion of circulating non-IgA plasmablasts exhibit a mucosal homing phenotype in SLE ( Figure 2B ). In this analysis, 75% of SLE plasmablasts expressed at least IgA or 1 mucosal homing receptor (median 75% [range 57-88%] for SLE patients [n 5 9] and median 81% [range 57-87%] for controls [n 5 14]; P 5 0.13) ( Figure 2C ). Since some IgA1 plasmablasts can also emerge from systemic immune responses ( Figure 2E ), we repeated the analysis without considering IgA expression. Here, 63% of control plasmablasts and 58% of SLE plasmablasts expressed b7 integrin, CCR10, or both (P 5 0.64), confirming that at least half of the plasmablasts carry a mucosal phenotype based on their homing receptor expression. We further analyzed the composition of plasmablasts by determining the frequencies of 8 plasmablast populations defined by the expression of IgA, CCR10, and b7 integrin. This approach revealed a trend toward lower frequencies of IgA1CCR101b7 integrinnegative plasmablasts and higher frequencies of IgA-CCR10-b7 integrin-negative plasmablasts in SLE, but the difference did not reach statistical significance (Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40181/abstract).
Finally, spontaneous secretion of polymeric IgA by unstimulated SLE PBMCs in 5 of 6 samples further supported the presence of at least some IgA1 plasmablasts in SLE blood that secrete antibodies dedicated to transepithelial transport at mucosal surfaces ( Figure 2D and Supplementary Figure 4 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40181/abstract).
Next, we validated the use of IgA, CCR10, and b7 integrin expression as markers of mucosal provenance in secondary oral cholera versus systemic tetanus vaccination studies, serving as models of mucosal (GI tract) versus parenteral plasmablast responses. As previously described (6, 23) , tetanus toxoid (TT)-specific plasmablasts were detectable 1 week after intramuscular booster vaccination. They predominantly expressed cytoplasmic IgG (median 82%) and rarely expressed cytoplasmic IgA (9%). Few, if any, TT-specific plasmablasts expressed CCR10 (median 7%) or b7 integrin (median 6%) ( Figure  2E ). Cholera toxin B (CTB) subunit-specific plasmablasts peaked 4 days after secondary vaccination in both donors analyzed ( Figure 2F and Supplementary Figure 5A , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40181/abstract). The specificity of CTB-specific plasmablast detection was confirmed by blocking the staining with unlabeled antigen (Supplementary Figure 5B ). CTB-specific plasmablasts expressed the phenotype IgA1/-, b7 integrin-positive, and CCR101/-in both donors analyzed ( Figure 2G ). Like other vaccineinduced plasmablasts (6, 27) , CTB-specific plasmablasts expressed the proliferation marker Ki-67, consistent with their recent differentiation from activated B cells (Supplementary Figure 5C ).
In summary, these results confirm the induction of IgA1/-, b7 integrin-positive, and CCR101/-plasmablasts in specific mucosal immune responses. A substantial fraction of plasmablasts in SLE expressed IgA, CCR10, or b7 integrin, and thus shares similarities with plasmablasts induced by mucosal vaccination. However, IgA-expressing and CCR10-expressing plasmablasts regularly contributed to plasmacytosis in SLE, while a contribution of b7 integrin-positive plasmablasts was seen in only a few patients.
Autoreactivity of IgA1 and IgG1 plasmablasts in SLE. We next addressed whether or not autoreactivity was limited to IgG1 plasmablasts. ELISpot was used Figure 2 . Mucosal phenotype of IgA1 plasmablasts (PBs) from patients with systemic lupus erythematosus (SLE). A, Top, Frequency of CCR10-expressing plasmablasts, number of CCR101 plasmablasts, and number of CCR10-plasmablasts in samples from healthy donors (HDs) and SLE patients. Bottom, Frequency of b7 integrin-expressing plasmablasts, number of b7 integrin-positive plasmablasts, and number of b7 integrin-negative plasmablasts in samples from healthy donors and SLE patients. Circles represent individual subjects; horizontal lines show the median. B, Representative gating of IgA1 and IgA-plasmablasts for coexpression of CCR10 and b7 integrin. Contour plots (from left to right) show 1,697, 969, 107, and 150 plasmablasts, respectively. C, Frequencies of plasmablasts expressing neither IgA, b7 integrin, nor CCR10 and frequencies of plasmablasts expressing at least 1 of these receptors in healthy donors and SLE patients. Circles represent individual subjects; horizontal lines show the median. P values were determined by Mann-Whitney test. D, Detection of plasmablasts secreting polymeric IgA (pIgA). Supernatants from SLE PBMCs cultured for 2 days under nonactivating conditions were subjected to size-exclusion chromatography. Fractions obtained were analyzed for IgA by enzyme-linked immunosorbent assay. Results for 4 of 6 samples analyzed are shown. Colostrum IgA was used as a reference to identify the fractions in which polymeric IgA was eluted (red bars) (see Supplementary Figure 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40181/abstract). E, Expression of CCR10, b7 integrin, cytoplasmic (cyt) IgG, and cytoplasmic IgA by recombinant tetanus toxin C-fragment (rTT.C)-specific plasmablasts. Dot plots show CD3-CD14-DAPI-CD191CD27 high CD20
-/low cells. Results are representative of 5 experiments. F, Cytometric identification of cholera toxin B (CTB) subunit-specific plasmablasts in peripheral blood after oral cholera vaccination. G, CCR10, b7 integrin, and IgA expression by CTB-specific and total plasmablasts. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001. Association of IgA and CCR10 expression by SLE plasmablasts with serum cytokine levels. We subsequently considered the possibility that the cytokine milieu present in SLE patients accounts for the amplification of plasmablast response in an autoantigenindependent manner. We determined serum concentrations of 25 cytokines from SLE blood samples, which were simultaneously analyzed for blood plasmablast characteristics by flow cytometry. A total of 28 parameters derived from manual gating of flow cytometric plasmablast data were classified according to whether they reflected systemic or mucosal plasmablast differentiation, based on the phenotype of vaccination-induced plasmablasts. Spearman's correlation analyses and subsequent bootstrap resampling revealed a serum cytokine signature comprising interleukin-2 (IL-2), IL-6, IL-17, platelet-derived growth factor BB (PDGF-BB), and vascular endothelial growth factor (VEGF) that directly correlated with frequencies of IgA1 and/or CCR101 plasmablasts (r s . 0), but not b7 integrin-positive plasmablasts (Figure 3) . Negative associations were found between levels of IL-12 and the expression of CD62L by plasmablasts. The emergence of phenotypically mucosal rather than parenteral plasmablasts was positively associated with serum cytokine levels in SLE (P , 0.0001 by Fisher's exact test). Few inverse correlations (r s , 0) were found when features of systemic plasmablast differentiation were analyzed. These were related to frequencies of plasmablasts lacking IgA and CCR10, and to the expression of CD62L, an adhesion molecule expressed by plasmablasts induced by intramuscular vaccination (6) .
A similar data set from healthy donors demonstrated a largely distinct pattern of plasmablast feature versus serum cytokine level correlations, suggesting that the pattern observed in SLE patients is associated with the disease, and not a general pattern observed in healthy individuals (data not shown).
SLE plasmablasts are migration competent.
While autoreactivity of B cells and cytokines may facilitate the plasmablast expansion in SLE patients' blood Figure 3 . Correlation of measures of mucosal, but not parenteral, plasmablast differentiation with serum cytokine levels in patients with systemic lupus erythematosus (SLE). Plasmablast data from 26 SLE patients and serum concentrations of 22 cytokines, determined by bead-based multiplex assay, were analyzed using Spearman's correlation. Levels of BAFF, APRIL, and interferon-a were determined separately by enzyme-linked immunosorbent assay and did not show correlations with plasmablast data (data not shown). Serum and plasmablast analyses were performed using the same donors and time points. Sera were treated with a heterophilic binding blocker to avoid potential interference by autoantibodies (55) . The matrix shows cytokines with at least 2 significant correlations (P , 0.05). Significant correlations confirmed by bootstrapping are shown in color according to their r s values. IL-2 5 interleukin-2; PDGF-BB 5 platelet-derived growth factor BB; VEGF 5 vascular endothelial growth factor; MFI 5 median fluorescence intensity.
by enhancing plasmablast production, we additionally considered impaired plasmablast mobility as seen in the NZM mouse model of SLE (28) as a potential mechanism contributing to blood plasmacytosis in SLE. We therefore analyzed in vitro chemotaxis of plasmablasts from SLE patients and controls toward CXCL12, CCL28, and CXCL9, which have been implicated in plasmablast homing to the bone marrow, mucosal tissues, and sites of autoimmune inflammation (20, 29) . Like control plasmablasts, plasmablasts from SLE patients were principally competent to migrate toward the chemokines tested, with a trend for enhanced migration toward CXCL9 in individual patients and somewhat decreased migration toward CXCL12 and CCL28 (Supplementary Figure 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40181/abstract). Since we found no evidence of principally impaired migration of SLE plasmablasts, plasmablasts appear to accumulate in the blood of SLE patients because of their overproduction rather than due to defective plasmablast migration.
PCs in inflamed kidneys are selected for IgG expression. Finally, we addressed whether the predominance of IgA1 plasmablasts in the peripheral blood of SLE patients is also evident at sites of chronic inflammation. We analyzed kidney biopsy specimens with lymphocytic infiltrates from 5 patients with active lupus nephritis (Supplementary Table 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40181/abstract) for the presence of cytoplasmic IgA1 and cytoplasmic IgG1 cells by fluorescence microscopy. This analysis provided a numerical ratio of 3:1 for IgG:IgA PCs (Figure 4) , documenting that IgG1 PCs are enriched over IgA1 PCs in inflamed kidneys in SLE. It remains unclear whether the observed kidney PCs were autoreactive or expressed mucosal homing receptor. The enrichment of IgG1 PCs in lupus nephritis supports the notion that they are more intimately involved in SLE tissue immunopathology than IgA1 PCs.
DISCUSSION
In this study, we show that major subsets of plasmablasts in the blood of SLE patients carry a phenotype reminiscent of mucosal immune reactions and that such phenotypically mucosal plasmablasts contribute to plasmablast expansion in SLE. Previous studies identified IgA1 plasmablasts as the minor (30,31) or major (32, 33) plasmablast subset in SLE. In the present study, on average 58% of the plasmablasts expressed IgA, indicating the predominance of IgA1 plasmablasts in SLE, while individual patients showed rather few IgA-expressing plasmablasts, amounting to 20-40% of total plasmablasts, or in ELISpot assays, excessive amounts of IgG-secreting cells. At least some of the IgA1 plasmablasts in the blood secreted polymeric IgA, dedicated to transepithelial transport at mucosal surfaces.
By including stainings for the mucosal homing receptors b7 integrin and CCR10 in our cytometric panel, we detected additional, apparently mucosal plasmablast subsets that do not produce IgA, such as CCR101 and/or b7 integrin-positive, IgM1, or IgG1 plasmablasts. The detection of these IgA2 subsets substantiates the emergence of mucosal plasmablasts in SLE: 40% of SLE plasmablasts expressed CCR10, and 38% expressed b7 integrin. Notably, IgA, CCR10, and b7 integrin were coexpressed in different patterns, ranging from plasmablasts expressing only 1 of the receptors to cells coexpressing all 3. Seventy-five percent of plasmablasts expressed at least 1 of these molecules. Our present results confirm previous observations (23, (34) (35) (36) that IgA1 plasmablasts can be byproducts of intramuscular vaccination responses, so that IgA expression alone may not serve as an unequivocal marker of mucosally induced plasmablasts. When only the expression of CCR10 and/or b7 integrin was considered, 58% of the plasmablasts qualified as mucosal plasmablasts.
As a reference for mucosally induced plasmablasts, we studied antigen-specific plasmablasts induced by oral cholera vaccination. This analysis showed that expression of IgA, CCR10, and b7 integrin was induced in the plasmablast population resulting from oral vaccination, yet only b7 integrin was expressed by virtually all CTB-specific plasmablasts. Unlike the CTB-specific plasmablasts, which almost uniformly expressed b7 integrin, SLE plasmablasts consisted of subpopulations expressing or lacking b7 integrin. This illustrates the heterogeneity of the plasmablast response in SLE and confirms that not all SLE plasmablasts qualify as mucosal plasmablasts.
Similar heterogeneity was recently observed in a study of blood plasmablast homing receptor signatures in patient groups with different mucosal immune syndromes. For example, plasmablasts from patients with upper respiratory tract infections showed a b7 integrin-negative CCR10 low/1 phenotype, plasmablasts from patients with ulcerative colitis were b7 integrin-positive/negative and CCR101, and plasmablasts from patients with celiac disease or symptoms of GI tract infection were b7 integrinpositive and CCR101, besides having varying expression of additional homing receptors. Our vaccination data and the findings of Seong et al and others (18, 21) support the notion that blood plasmablasts in SLE represent a mixture of plasmablasts induced in different tissues, with diverse mucosal sites contributing plasmablasts with different b7 integrin/CCR10 phenotypes. This appears to be consistent with the systemic inflammation evident in SLE, which includes mucosal tissues in some patients.
Notably, mucosal priming does not exclude homing of the resultant plasmablast to the bone marrow (37) , indicating that mucosal and parenteral plasmablast migration routes are not fully separated. The absence of CLA and CCR9 expression on plasmablasts is evidence against selective intestinal and skin homing as major plasmablast migration routes in SLE.
Since an unequivocal phenotypic definition of mucosal plasmablasts is lacking, true enumeration of unambiguously mucosal plasmablasts and their assignment to specific mucosal tissues was not possible. However, our data clearly show that, unexpectedly, plasmablasts with a mucosal phenotype make up a significant fraction of total plasmablasts in SLE and that plasmablasts expressing IgA in combination with CCR10 contribute to the plasmablast expansion in SLE patients. In this study, we reproduced the typical expansion of frequencies and absolute numbers of plasmablasts in active SLE when comparing patients with active versus inactive disease using an SLE Disease Activity Index (SLEDAI) threshold of 6. However, a close and significant correlation between plasmablast numbers and disease activity could not be established in our study, possibly because of the inclusion of patients who had received previously unavailable treatments, such as anti-BAFF (belimumab) or B cell depletion, and also because patients were included from both inpatient and outpatient settings. While plasmablast expansion was detectable in patients in both groups, our prior studies on plasmablasts in SLE (2, 4, 38) were performed almost exclusively among hospitalized patients, who have enhanced disease activity compared to outpatients.
We found no evidence of an association between frequencies of IgA1, CCR101, or b7 integrin-positive plasmablasts among total plasmablasts and disease activity or the overall emergence of plasmablasts. This suggested that the contribution of IgA1, CCR101, or b7 integrin-positive plasmablasts to the overall plasmablast population in SLE is relatively stable and independent of disease activity and severity of plasmacytosis.
Unlike in blood, PCs in chronically inflamed kidneys of SLE patients were dominated by the IgG isotype in all cases analyzed, supporting the involvement of IgG-secreting cells in lupus nephritis pathology. It remained unclear whether PCs detectable in the kidneys had migrated there, were generated in situ, or were a mixture of both.
The intriguingly similar composition of SLE and control plasmablasts led us to speculate that plasmacytosis in SLE was largely due to unselective amplification of the normal steady-state plasmablast response (6) . However, we detected autoreactive cells among IgGand IgA-secreting cells, showing that at least some IgA1 plasmablasts do not belong to the homeostatic plasmablast repertoire seen in healthy controls, and peripheral blood IgA1 plasmablasts are not principally spared from autoreactivity. Our comparison of serum cytokine levels with plasmablast features indicating preferentially mucosal versus parenteral induction revealed a set of cytokines that was positively associated with the emergence of mucosal (IgA1 and/or CCR101) plasmablasts but was not associated, or was negatively associated, with the emergence of parenteral plasmablasts. This cytokine signature included IL-2, IL-6, IL-17, PDGF-BB, and VEGF, with IL-2 and PDGF-BB having greater numbers of associations. PDGF-BB is known to be a regulator of mesangial cells and is implicated in nephropathy (39) , and has also been linked to both proinflammatory and antiinflammatory roles (40, 41) , DISTINCT PLASMABLAST SUBSETS IN SLE 2025 although direct interactions with mature B cells or PCs have not been described. Treg cells are candidates for a possible link between IL-2 and the emergence of mucosal plasmablasts. Treg cells produce the IgA class-switchinducing cytokine TGFb (42) , and IL-2 therapy increases Treg cell frequencies and activation state in the blood of SLE patients (43, 44) . Treg cell depletion in mice decreases the amounts of lamina propria IgA1 PCs and IgA antibodies (45) . Notably, serum levels of PDGF-BB and TGFb have been found to be associated in a study of chronic pancreatitis (46) . In addition, IL-2 may selectively promote differentiation of CD271 CD251IgA1/-memory B cells, which, when activated, likewise secrete TGFb (47) . In contrast, IL-6, which belongs to the group of inflammation-promoting cytokines, stimulates the proliferation of B cells activated by IL-2 or IL-10, promotes the survival of PCs, and likely promotes plasmablasts expressing the IL-6 receptor (48, 49) . Some, but not all, human blood plasmablasts express the IL-6 receptor (50), and IL-6 has been shown to be required for normal IgA production in vivo (51) . A network of IL-2, TGFb, and IL-6 appears to control Treg cells and Th17 cells (52) , which are implicated in both IgA production (53) and autoimmune pathogenesis (54) . However, the nature of our cytokine/plasmablast comparison is purely associative and requires further mechanistic studies.
Taken together, the cytokine signature identified is, with the exception of PDGF-BB and VEGF, consistent with the involvement of cytokine signals that either directly or via T cells can impact the quality and quantity of plasmablast responses.
Finally, we tested the hypothesis that the enrichment of plasmablasts in SLE blood might be due to a migration defect interfering with the plasmablast's exit from blood. In Transwell chemotaxis assays, SLE plasmablasts showed a somewhat enhanced response toward CXCL9 implicated in plasmablast recruitment to inflamed sites. Migration responses toward CXCL12 and CCL28, reflecting the functionality of CXCR4 and CCR10, were largely comparable to controls, and confirmed that SLE plasmablasts chemotactically respond normally, at least under in vitro conditions. In summary, our data document the participation of mucosal plasmablasts in the exaggerated plasmablast response in SLE, reflecting an overactivation and involvement of the mucosal immune system in SLE. The heterogeneity of plasmablasts in SLE appears to be due to superimposed B cell hyperactivity driven by autoreactivity and the cytokine environment. Further studies are needed to evaluate how immune therapies influence mucosal immune activity in SLE and whether additional treatment considerations are required.
